Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE)...
-
Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service ExpansionComprehensive CDMO services now featured on Biomerica’s updated website IRVINE, Calif., Nov. 06,...
-
- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica’s Commercialization...
-
Biomerica reports Q1 FY2026 results highlighting improved margins, cost reductions, and progress in advancing diagnostics and CDMO operations.
-
Brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy, and sales growth Extensive track record in commercializing advanced laboratory testing and insurer strategies...
-
New AI-enabled digital tool empowers patients to confidently manage IBS symptoms and avoid the trigger foods identified by inFoods® IBS testingIBS affects an estimated 40 million adults in the U.S....
-
10-minute home test detects early kidney damage in diabetic and hypertensive patientsHypertension affects roughly one-third of adults in the UAEDiabetes impacts approximately one in four UAE nationals...
-
Biomerica 2025 Fiscal Year End Results
-
10-minute home test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerH. pylori linked to approximately 80% of gastric cancer cases; classified...
-
PLA Code issuance by the American Medical Association CPT editorial panel marks a meaningful step toward attaining health insurance reimbursement and expanded patient access for inFoods® IBSinFoods®...